At the crossroads of two of modern medicine's most pressing challenges—obesity and heart disease—a real-world study presented in Madrid has offered a striking, if provisional, answer to a question that millions of patients and their physicians are quietly asking: not all weight-loss drugs are equal when the heart is at stake. Novo Nordisk's STEER study, drawing on the clinical histories of more than 21,000 Americans, found that semaglutide reduced the risk of heart attack, stroke, or death by 57 percent more than tirzepatide among patients who carried both obesity and established cardiovascula
Wegovy cuts cardiovascular death risk 57% more than tirzepatide in real-world study
The cardiovascular protection appears specific to semaglutide itself
Mark
So Novo Nordisk is saying their drug Wegovy cuts heart attack and stroke risk 57 percent better than tirzepatide. That's a huge number. How solid is that claim?
Mimi
The study tracked over 21,000 real patients in actual clinical practice, not a controlled trial. They matched patients on similar characteristics to make the groups comparable. But here's the thing—the absolute numbers were small. Fifteen cardiovascular events in the Wegovy group, 39 in the tirzepatide group. The percentage difference is large, but we're talking about rare events in both groups.
Luke
And the follow-up was short. About four months for people who stayed on treatment consistently. We don't know if this advantage holds at one year, two years, five years. Real-world studies are useful, but they're not randomized. There could be unmeasured differences between who chose Wegovy and who chose tirzepatide that explain some of the gap.
Mark
But didn't Novo Nordisk's earlier SELECT trial show cardiovascular benefits with Wegovy compared to placebo?
Mimi
Yes, SELECT was randomized and showed a 20 percent reduction in major cardiovascular events. That's solid evidence. This new STEER study is comparing Wegovy directly to tirzepatide, not to placebo, so it's answering a different question—which of these two drugs is better for heart protection in obese patients with existing heart disease.
Luke
The company is making a big claim that semaglutide's benefits are specific to that molecule and don't apply to other GLP-1 drugs or tirzepatide. But this is one study. We'd want to see that replicated independently before treating it as settled science.
Mark
Why would the benefits be specific to semaglutide if they're all in the same drug class?
Mimi
Different molecules work slightly differently, even within the same class. Semaglutide might have properties beyond just activating the GLP-1 receptor that protect the heart. But we don't have a clear mechanism yet. That's part of what makes this interesting—and uncertain.
Luke
And worth noting: Novo Nordisk funded this study and presented it at their own conference. That doesn't mean the data is wrong, but it's worth being cautious about accepting the strongest interpretation without independent verification.
O Pulso
- A 57% relative reduction in major cardiovascular events separates Wegovy from tirzepatide in the STEER study, a gap too large for clinicians to easily set aside when choosing between two widely prescribed medications.
- The absolute numbers are small—15 events versus 39 over roughly four months—but the direction is consistent with earlier randomized trial data, creating a pattern that is difficult to dismiss as coincidence.
- Because STEER was observational and funded by Novo Nordisk, critics will scrutinize whether unmeasured patient differences, not the drug itself, drove the outcome—a tension the research community will not resolve quickly.
- Tirzepatide has rapidly captured market share and clinical enthusiasm, meaning these findings land in a competitive landscape where billions of dollars and millions of prescriptions hang in the balance.
- Researchers and guideline writers now face pressure to determine whether semaglutide's apparent heart protection is a molecule-specific phenomenon—a question that only longer, independent, and ideally randomized studies can settle.
At the crossroads of two of modern medicine's most pressing challenges—obesity and heart disease—a real-world study presented in Madrid has offered a striking, if provisional, answer to a question that millions of patients and their physicians are quietly asking: not all weight-loss drugs are equal when the heart is at stake. Novo Nordisk's STEER study, drawing on the clinical histories of more than 21,000 Americans, found that semaglutide reduced the risk of heart attack, stroke, or death by 57 percent more than tirzepatide among patients who carried both obesity and established cardiovascular disease. The finding does not close the debate, but it deepens it—suggesting that the cardiovascular benefit observed with Wegovy may belong to the molecule itself, not merely to the class of drugs it represents.
Novo Nordisk this week unveiled findings from its STEER study at the European Society of Cardiology Congress in Madrid, comparing Wegovy and tirzepatide in patients who were both obese and living with established heart disease. Among the more than 21,000 Americans tracked in routine clinical care since May 2022, those who took semaglutide consistently saw their risk of heart attack, stroke, or death fall 57 percent more than those on tirzepatide. The absolute event counts were modest—15 in the Wegovy group against 39 in the tirzepatide group—but the relative gap was striking enough to draw immediate attention.
The study was retrospective and observational, not randomized. Researchers used propensity score matching to align the two groups of roughly 10,625 patients each, balancing age, weight, and existing conditions. Average follow-up in the primary analysis ran to about four months. These design features matter: without random assignment, unmeasured differences between groups could theoretically account for some of the advantage, and the short observation window limits what can be said about long-term protection.
The STEER results nonetheless extend a consistent pattern. Novo Nordisk's earlier SELECT trial—a randomized, double-blind study—had already shown Wegovy reducing major cardiovascular events by 20 percent compared to placebo in similar patients. A separate real-world study called SCORE pointed in the same direction. Taken together, the evidence has led Novo Nordisk to argue that semaglutide's cardiovascular benefit is specific to the molecule itself and cannot be assumed to transfer to other GLP-1 or dual GIP/GLP-1 drugs like tirzepatide.
The stakes are considerable. Cardiovascular disease claims nearly 21 million lives each year, and obesity-related heart deaths have risen sharply even as overall cardiovascular mortality has declined. For patients navigating both conditions at once, the choice of medication is no longer purely a question of weight loss. Whether independent researchers confirm these findings over longer time horizons will determine how much weight the medical community ultimately gives them—and how profoundly they reshape the prescribing landscape.
Novo Nordisk presented findings this week from a real-world study comparing two obesity medications in patients who already had heart disease, and the results heavily favored the company's own drug. The STEER study, unveiled at the European Society of Cardiology Congress in Madrid on August 31, tracked over 21,000 patients in the United States who began treatment with either Wegovy (semaglutide 2.4 mg) or tirzepatide starting in May 2022. Among those who took their medication consistently without gaps longer than 30 days, Wegovy reduced the risk of heart attack, stroke, or death from any cause by 57 percent more than tirzepatide did. The absolute numbers were small—15 cardiovascular events in the Wegovy group versus 39 in the tirzepatide group—but the relative difference was striking.
The study design matters here. STEER was retrospective and observational, meaning researchers looked backward at what actually happened to patients in routine clinical care rather than randomly assigning people to treatment arms in a controlled trial. The researchers used propensity score matching to make the two groups as comparable as possible, balancing characteristics like age, weight, and existing health conditions. Each group contained 10,625 people aged 45 and older with obesity or overweight and established cardiovascular disease but no prior diabetes diagnosis. The average follow-up was roughly four months for both groups, though when the analysis included everyone regardless of treatment gaps, the observation period stretched to about eight months.
This real-world evidence builds on earlier controlled research. Novo Nordisk's SELECT trial, a randomized double-blind study published in 2023, showed that Wegovy reduced major cardiovascular events by 20 percent compared to placebo in similar patients. Another real-world study called SCORE, conducted in US clinical practice, also found cardiovascular benefits with semaglutide. Ludovic Helfgott, Novo Nordisk's executive vice president for product strategy, framed the new findings as confirmation that semaglutide stands apart: "This data confirms that semaglutide stands apart as the only available GLP-1-based medication with proven cardiovascular benefits for people living with obesity and cardiovascular disease, without diabetes."
The company emphasized a crucial distinction. The cardiovascular protection observed with Wegovy appears specific to the semaglutide molecule itself and cannot be assumed to extend to other medications in the same drug class—other GLP-1 receptor agonists or the newer dual GIP/GLP-1 receptor agonists like tirzepatide. This matters because tirzepatide, marketed as Zepbound for weight loss and Mounjaro for diabetes, has gained significant market share and clinical adoption since its approval. If semaglutide's heart benefits are truly molecule-specific, that distinction could reshape how doctors think about which medication to prescribe for obese patients with existing heart disease.
The broader context underscores why this comparison matters. Cardiovascular disease kills nearly 21 million people annually worldwide and remains the leading cause of disability and death globally. Obesity directly contributes to cardiovascular illness, hospitalization, and death. While cardiovascular mortality has declined over the past two decades, deaths specifically linked to obesity-related cardiovascular disease have climbed sharply—two in three obesity-related deaths now involve the heart or blood vessels. For patients caught in that intersection of obesity and existing heart disease, the choice of medication could carry real weight.
The STEER study has limitations worth noting. It was not randomized, so unmeasured differences between the groups could theoretically explain some of the gap. The follow-up period was relatively short—under four months for the primary analysis. The study population was drawn from a single US database and may not represent all patients with obesity and heart disease. Novo Nordisk funded the research and presented it at a major cardiology conference, which is standard practice but worth keeping in mind when interpreting the findings.
Still, the data point in a consistent direction across multiple studies. If confirmed in longer-term research and in different populations, these results could influence treatment guidelines and clinical practice for millions of patients. The question now is whether other researchers will independently verify these findings and whether the cardiovascular advantage holds up as patients take these medications over years rather than months.
Citações Notáveis
This data confirms that semaglutide stands apart as the only available GLP-1-based medication with proven cardiovascular benefits for people living with obesity and cardiovascular disease, without diabetes.— Ludovic Helfgott, executive vice president and head of Product & Portfolio Strategy at Novo Nordisk
Quer a matéria completa?
Leia o original em The Manila Times ↗
Health & Medicine